Patient-Reported Outcomes of PD-1 Inhibitor Camrelizumab Combined with Antiangiogenic Drug Apatinib in Patients with Advanced Cervical Cancer
10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.2022.0409
- VernacularTitle:复发/转移宫颈癌患者应用PD-1抑制剂卡瑞利珠单抗联合阿帕替尼治疗的患者报告结局
- Author:
Yue-rong LAI
1
;
Yue JIANG
1
;
Xin HUANG
1
;
Yu-lan OU
1
Author Information
1. Department of Gynecology， Sun Yat-sen University Cancer Center， Guangzhou 510060， China
- Publication Type:Journal Article
- Keywords:
cervical cancer;
immune checkpoint inhibitors;
targeted therapy;
patient-reported outcome
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2022;43(4):591-599
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveA previous multicenter， single-arm phase Ⅱ clinical study evaluated the efficacy and safety of the PD-1 inhibitor camrelizumab in combination with the antiangiogenic drug apatinib in patients with recurrent/metastatic cervical cancer. In the current study， we aimed to report the patient-reported outcomes （PRO） in patients with advanced cervical cancer. MethodsThe researchers filled out quality of life questionnaire FACT-Cx with the patients face-to-face at the baseline and every two treatment cycles. The patients provided the questionnaire until disease progression. For patients who continued the study， the data cutoff date for the questionnaire was Oct12， 2020. ResultsIn this study， 41 patients who received treatment finished at least one FACT-Cx questionnaire. The scores of FACT-Cx questionnaire at baseline， the first 6 cycles， and after 6 cycles of treatment （range， 7-15cycle） were 114.53±18.23， 124.08±15.23 and 132.82±21.97， respectively. The scores of questionnaire at the first 6 cycle and after 6 cycles of treatment were significantly increased when compared with those at baseline （P＜0.05）. With respect to each dimension of the FACT-Cx questionnaire， physical status （such as mental state， limb pain）， emotional status （such as sadness， tension）， functional status （such as daily activities） and additional concerns （such as sexual function）， the average scores of these dimensions was significantly higher after 6 treatment cycles than those at baseline （P<0.05）. Social/family status dimensions （such as family relationships） did not change significantly. In the first 6 cycles， the incidence of grade 3 to 4 adverse events （AEs） was 71.11%. However， the incidence of grade 3 to 4 AEs decreased significantly to 25.0% after 6 treatment cycles， with the frequencies of hypertension and fatigue decreasing significantly. ConclusionsCamrelizumab combined with apatinib significantly improves the overall quality of life of patients with recurrent/metastatic cervical cancer. The scores of FACT-Cx questionnaire in multiple dimensions， such as physiological status， emotional status， functional status， and the additional status were significantly increased. Moreover， the questionnaire scores still increase after 6 treatment cycles compared with those of the first 6 cycles， indicating that the improvement of quality of life is durable.
